Skip Page Header

Home > Items where Subject is "B Substances > Cannabis product (Cannabinoids) > Cannabinol / Cannabidiol (CBD oil)"

Up a level
Export as
Group by: Item Type | No Grouping
Number of items at this level: 55.


Crippa, José Alexandre S and Zuardi, Antonio W and Guimarães, Francisco S and Campos, Alline Cristina and de Lima Osório, Flávia and Loureiro, Sonia Regina and Dos Santos, Rafael G and Souza, José Diogo S and Ushirohira, Juliana Mayumi and Pacheco, Julia Cozar and Ferreira, Rafael Rinaldi and Mancini Costa, Karla Cristinne and Scomparin, Davi Silveira and Scarante, Franciele Franco and Pires-Dos-Santos, Isabela and Mechoulam, Raphael and Kapczinski, Flávio and Fonseca, Benedito A L and Esposito, Danillo L A and Pereira-Lima, Karina and Sen, Srijan and Andraus, Maristela Haddad and Hallak, Jaime E C (2021) Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and burnout among frontline health care workers during the COVID-19 pandemic: a randomized clinical trial. JAMA Network Open , 4 , (8) , e2120603.

Anderson, Lyndsey L and Etchart, Maia G and Bahceci, Dilara and Golembiewski, Taliesin A and Arnold, Jonathon C (2021) Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations. Scientific Reports , 11 , (14948) .

Freeman, Tom P and Craft, Sam and Wilson, Jack and Stylianou, Stephan and ElSohly, Mahmoud and Di Forti, Marta and Lynskey, Michael T (2021) Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. Addiction , 116 , (5) , pp. 1000-1010.

Farrelly, Aaron M and Vlachou, Styliani and Grintzalis, Konstantinos (2021) Efficacy of phytocannabinoids in epilepsy treatment: novel approaches and recent advances. International Journal of Environmental Research and Public Health , 18 , (8) , p. 3993.

Gilman, Jodi M and Schmitt, William A and Wheeler, Grace and Schuster, Randi M and Klawitter, Jost and Sempio, Cristina and Evins, A Eden (2021) Research letter: Variation in cannabinoid metabolites present in the urine of adults using medical cannabis products in Massachusetts. JAMA Network Open , 4 , (4) , e215490.

Analakkattillam, S and Langsi, V K and Hanrahan, J P and Moore, E (2021) Comparative study of dissolution for cannabidiol in EU and US hemp oil products by HPLC. Journal of Pharmaceutical Sciences , 110 , (8) , pp. 3091-3098.

Krishnan, Aditya and Chizo Agwu, Juliana and Kallappa, Chetana and Pandey, Ragesh (2021) Case report. Development of central precocious puberty following cannabinoid use for paediatric epilepsy: causal or coincidence? BMJ Case Reports , 14 , e239678.

Velayudhan, Latha and McGoohan, Katie and Bhattacharyya, Sagnik (2021) Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis. PLoS Medicine , 18 , (3) , e1003524.

Schlag, Anne K and Hindocha, Chandni and Zafar, Rayyan and Nutt, David J and Curran, H Valerie (2021) Cannabis based medicines and cannabis dependence: a critical review of issues and evidence. Journal of Psychopharmacology .

Mongeau-Pérusse, Violaine and Brissette, Suzanne and Bruneau, Julie and Conrod, Patricia and Dubreucq, Simon and Gazil, Guillaume and Stip, Emmanuel and Jutras-Aswad, Didier (2021) Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo-controlled trial. Addiction , 116 , (9) , pp. 2431-2442.

Morel, Alix and Lebard, Pierre and Dereux, Alexandra and Azuar, Julien and Questel, Frank and Bellivier, Frank and Marie-Claire, Cynthia and Fatséas, Mélina and Vorspan, Florence and Bloch, Vanessa (2021) Clinical trials of cannabidiol for substance use disorders: outcome measures, surrogate endpoints, and biomarkers. Frontiers in Psychiatry , 12 , p. 565617.

Jones, Éamon and Vlachou, Styliani (2020) A critical review of the role of the cannabinoid compounds Δ-tetrahydrocannabinol (Δ-THC) and cannabidiol (CBD) and their combination in multiple sclerosis treatment. Molecules , 25 , (21) .

McGregor, Iain S and Cairns, Elizabeth A and Abelev, Sarah and Cohen, Rhys and Henderson, Mat and Couch, Daniel and Arnold, Jonathon C and Gauld, Natalie (2020) Access to cannabidiol without a prescription: a cross-country comparison and analysis. International Journal of Drug Policy , 85 , p. 102935.

Millar, Sophie Anne and Maguire, Ryan Francis and Yates, Andrew Stephen and O'Sullivan, Saoirse Elizabeth (2020) Towards better delivery of cannabidiol (CBD). Pharmaceuticals , 13 , (9) .

American Heart Association Clinical Pharmacology Committee and Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, Council on Basic Cardiovascular Sciences, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention; Council on Lifestyle and Cardiometabolic Health, Council on Quality of Care and Outcomes Research. Medical marijuana, recreational cannabis, and cardiovascular health. Paige II, Robert L and Allen, Larry A and Kloner, Robert A and Carriker, Colin R and Martel, Catherine and Morris, Alanna A and Piano, Mariann R and Rana, Jamal S and Saucedo, Jorge F (2020) Medical marijuana, recreational cannabis, and cardiovascular health: a scientific statement from the American Heart Association. Circulation , 142 .

Cather, Jennifer Clay and Cather, J Christian (2020) Cannabidiol primer for healthcare professionals. Baylor University Medical Center proceedings , 33 , (3) .

Hindley, Guy and Beck, Katherine and Borgan, Faith and Ginestet, Cedric E and McCutcheon, Robert and Kleinloog, Daniel and Ganesh, Suhas and Radhakrishnan, Rajiv and D'Souza, Deepak Cyril and Howes, Oliver D (2020) Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. The Lancet Psychiatry , 7 , (4) , pp. 344-353.

Lancet Press Office. (2020) The Lancet Psychiatry: Single dose of psychoactive component in cannabis could induce psychotic, depressive, and anxiety symptoms in healthy people. EurekAlert .

Lipnik-Štangelj, Metoda and Razinger, Barbara (2020) A regulatory take on cannabis and cannabinoids for medicinal use in the European Union. Archives of Industrial Hygiene and Toxicology , 71 , (1) , pp. 12-18.

Brody, Herb (2019) Cannabis: a field in flux. Nature Outlook , 572 , (S1) .

Brown, Joshua D and Winterstein, Almut G (2019) Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine , 8 , (7) .

Freeman, Tom P and Hindocha, Chandni and Green, Sebastian F and Bloomfield, Michael AP (2019) Medicinal use of cannabis based products and cannabinoids. BMJ (Clinical Research ed.) , 365 , l1141.

Fennessy, Paul and Murphy, L and Crowe, S (2018) Cannabis oil in an Irish children’s critical care unit. Irish Medical Journal , 111 , (8) .

Stockings, Emily and Zagic, Dino and Campbell, Gabrielle and Weier, Megan and Hall, Wayne D and Nielsen, Suzanne and Herkes, Geoffery K and Farrell, Michael and Degenhardt, Louisa (2018) Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. Journal of Neurology, Neurosurgery and Psychiatry , 89 , (7) .

Fischer, Benedikt and Russell, Cayley and Sabioni, Pamela and van den Brink, Wim and Le Foll, Bernard and Hall, Wayne and Rehm, Jürgen and Room, Robin (2017) Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations. American Journal of Public Health , 107 , (8) , e1-e12.

McLoughlin, Benjamin C and Pushpa-Rajah, Jonathan A and Gillies, Donna and Rathbone, John and Variend, Hannele and Kalakouti, Eliana and Kyprianou, Katerina (2014) Cannabis and schizophrenia. Cochrane Database of Systematic Reviews , (10) .

Bloomfield, Michael A P and Hindocha, Chandni and Green, Sebastian F and Wall, Matthew B and Lees, Rachel and Petrilli, Katherine and Costello, Harry and Olabisi Ogunbiyi, M and Bossong, Matthijs G and Freeman, Tom P The neuropsychopharmacology of cannabis: a review of human imaging studies. Pharmacology & Therapeutics .


National Institute for Health and Care Excellence. (2021) Cannabis-based medicinal products. London: NICE.

European Monitoring Centre for Drugs and Drug Addiction. (2020) Low-THC cannabis products in Europe. Luxembourg: Publications Office of the European Union.

PDQ Integrative, Alternative and Complementary Therapies Editorial Board. (2020) PDQ Cannabis and cannabinoids. Bethesda, MD: National Cancer Institute.

Therapeutic Goods Administration. (2020) Safety of low dose cannabidiol. ACT, Australia: Australian Government Department of Health.

Ireland. Department of Health. (2020) Medical cannabis access programme. Dublin: Department of Health.

Food Safety Authority. (2020) Survey: regulatory issues with hemp-based food and food supplements on the Irish market. Dublin: Food Safety Authority.

WHO Expert Committee on Drug Dependence. (2017) 39th Expert Committee on Drug Dependence: technical documents. Geneva: World Health Organization.

WHO Expert Committee on Drug Dependence. (2017) Cannabidiol (CBD) pre-review report. Agenda item 5.2. Geneva: World Health Organization.

Health Products Regulatory Authority. (2017) Cannabis for medical use - a scientific review. Dublin: Department of Health.

Barnes, Michael P and Barnes, Jennifer C (2016) Cannabis: the evidence for medical use. London: All-Party Parliamentary Group for Drug Policy Reform.

National Centre for Pharmacoeconomics. (2013) Delta-9-tetrahydrocannabinol (THC) /Cannabidiol (CBD) (Sativex®). Dublin: National Centre for Pharmacoeconomics.


Irish College of Psychiatrists. (2021) Cannabidiol (CBD) and CBD products. Dublin: Irish College of Psychiatrists.

Irish College of Psychiatrists. (2020) The effects of cannabis on mental health. Information sheet for health professionals. Dublin: Irish College of Psychiatrists.

National Institute on Drug Abuse. (2019) DrugFacts: Marijuana as medicine. Bethesda, MD: National Institute on Drug Abuse.

Dail Debates

[Oireachtas] Dail Eireann debate. Questions on promised legislation [Medicinal cannabis]. (12 Jun 2019)

[Oireachtas] Dail Eireann debate. Topical issue debate – Misuse of drugs [CBD]. (11 Jun 2019)

[Oireachtas] Dail Eireann debates. Written answer 878 - Cannabis for medicinal use [15907/18]. (17 Apr 2018)

[Oireachtas] Dail Eireann debate. Written answer 432 - Misuse of drugs [8277/17] [CBD]. (21 Feb 2017)

[Oireachtas] Dail Eireann debate. Written answer 472 - Medicinal products licensing [Cannabidiol medical marijuana] [11587/16]. (24 May 2016)


[Irish Examiner] , Dunphy, Liz First cannabis-based product under MCAP to be available from next month. (29 Sep 2021)

[Food Safety Authority of Ireland] Recall of various CBD food supplements due to the presence of unsafe levels of delta‐9‐tetrahydrocannabinol (THC). (27 Jul 2021)

[Medical Independent] , Reilly, Catherine Epilepsy specialists call for inclusion of purified CBD product in access programme. (04 Jun 2021)

[Food Safety Authority of Ireland] FSAI issues warning on edible products (sweets) containing cannabis. (26 Apr 2021)

[] , Halpin, Hayley Provision for delivery and funding of Medicinal Cannabis Access Programme announced. (21 Jan 2021)

[] , Ryan, Orla 'If we sell CBD as a 'cure-all' for everything, it will drown out what it is actually effective for'. (26 Dec 2019)

[] , Finn, Christina Two medicinal cannabis products approved for use in Ireland. (03 Dec 2019)

[Irish Times] , O'Connell, Jennifer CBD: What’s the story with this legal cannabis constituent? (01 Dec 2018)

[] , Duffy, Ronan Confused about CBD? Here's what you need to know about Ireland and the cannabis-based remedy. (21 Jul 2018)

This list was generated on Tue Oct 26 04:06:44 2021 IST.